Diplomat Pharmacy, Inc. (NYSE:DPLO) was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued to investors on Friday.

A number of other research firms also recently commented on DPLO. TheStreet upgraded Diplomat Pharmacy from a “d+” rating to a “c-” rating in a report on Thursday, August 10th. Zacks Investment Research upgraded Diplomat Pharmacy from a “sell” rating to a “hold” rating in a report on Wednesday, August 9th. Needham & Company LLC started coverage on Diplomat Pharmacy in a report on Friday, July 21st. They issued a “buy” rating and a $19.75 price objective for the company. Finally, Bank of America Corporation upped their price objective on Diplomat Pharmacy from $17.00 to $18.50 and gave the company a “neutral” rating in a report on Thursday, May 25th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating and two have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $17.89.

Diplomat Pharmacy (DPLO) traded up 0.97% during trading on Friday, hitting $19.68. The company had a trading volume of 1,822,893 shares. The firm has a 50-day moving average of $16.70 and a 200 day moving average of $16.22. Diplomat Pharmacy has a 12-month low of $12.25 and a 12-month high of $31.33. The company has a market capitalization of $1.34 billion, a price-to-earnings ratio of 107.54 and a beta of 0.65.

Diplomat Pharmacy (NYSE:DPLO) last released its quarterly earnings data on Monday, August 7th. The company reported $0.25 EPS for the quarter, beating analysts’ consensus estimates of $0.15 by $0.10. The business had revenue of $1.13 billion during the quarter, compared to the consensus estimate of $1.14 billion. Diplomat Pharmacy had a return on equity of 7.97% and a net margin of 0.27%. The firm’s revenue was up 3.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.23 earnings per share. On average, equities research analysts forecast that Diplomat Pharmacy will post $0.75 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This news story was reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/16/diplomat-pharmacy-inc-dplo-lifted-to-hold-at-bidaskclub.html.

A number of large investors have recently bought and sold shares of the business. Louisiana State Employees Retirement System grew its stake in Diplomat Pharmacy by 0.6% in the second quarter. Louisiana State Employees Retirement System now owns 17,800 shares of the company’s stock valued at $263,000 after acquiring an additional 100 shares during the period. Capstone Asset Management Co. grew its stake in Diplomat Pharmacy by 0.5% in the second quarter. Capstone Asset Management Co. now owns 24,430 shares of the company’s stock valued at $362,000 after acquiring an additional 120 shares during the period. Texas Permanent School Fund grew its stake in Diplomat Pharmacy by 0.5% in the first quarter. Texas Permanent School Fund now owns 31,420 shares of the company’s stock valued at $501,000 after acquiring an additional 164 shares during the period. Arizona State Retirement System grew its stake in Diplomat Pharmacy by 0.9% in the second quarter. Arizona State Retirement System now owns 22,800 shares of the company’s stock valued at $337,000 after acquiring an additional 200 shares during the period. Finally, Bank of Montreal Can grew its stake in Diplomat Pharmacy by 3.0% in the second quarter. Bank of Montreal Can now owns 11,600 shares of the company’s stock valued at $172,000 after acquiring an additional 340 shares during the period. 69.89% of the stock is owned by hedge funds and other institutional investors.

About Diplomat Pharmacy

Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.

Analyst Recommendations for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.